Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J. Lamble, Nirali N. Shah, Regina M. Myers et al.|Blood Advances|2022Cited by 149
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapyEmily M. Hsieh, Regina M. Myers, Bonnie Yates et al.|Blood Advances|2022Cited by 34
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara Silbert, Marlie R. M. Provost, Raymund S. Cuevo et al.|Blood|2025Cited by 33
Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free SurvivalAgne Taraseviciute, Nirali N. Shah, Seth M. Steinberg et al.|Blood|2020Cited by 24
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Kara L. Davis, Jolanda Sarno et al.|Nature Communications|2025Cited by 18